

**ALKEM LABORATORIES LTD.**

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

13th February, 2026

To,

The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. <i>Scrip Code: 539523</i>	National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai 400 051. <i>Scrip Symbol: ALKEM</i>
---	--

Sub: Press Release and Analyst Presentation on Q3 & 9MFY26 Results

Dear Sir(s) / Madam,

With reference to relevant provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the press release and analyst presentation on Q3 & 9MFY26 earnings and business updates and the same will be uploaded on the website of the Company.

Kindly take a note of the same.

Sincerely,
For **Alkem Laboratories Limited**

Manish Narang
President - Legal, Company Secretary & Compliance Officer

Encl.: a/a

Press Release

Alkem reports 11% revenue growth in Q3 FY26.

Mumbai, February 13, 2026: Alkem Laboratories Ltd. today announced its standalone and consolidated financial results for the third quarter ended December 31, 2025. The Board of Directors took record of these results at its meeting held in Mumbai today.

Key Financial Metrics



Also, Alkem Laboratories announced the execution of a binding term sheet for acquiring a majority stake in Occlutech Holding AG (“Occlutech”), a global medical devices company, headquartered in Switzerland, specialising in minimally invasive cardiac implants, through its wholly-owned subsidiary Alkem MedTech Pvt Ltd (“Alkem MedTech”).

Commenting on this development, Sandeep Singh, Managing Director, Alkem Laboratories said, “This acquisition holds strategic importance as we work towards establishing a global footprint in medical devices. Occlutech is the third-largest player globally in the minimally invasive cardiac implants segment. With its significant presence in high-barrier markets, best-in-class R&D and manufacturing, and robust quality systems, Occlutech provides a strong lever for Alkem MedTech to expand into cardiovascular along with orthopaedics. Medtech is a natural extension for Alkem. In the company years, along with Enzene Biosciences, our Biotech arm, we expect Alkem MedTech to become meaningful growth pillar for the company.”

Commenting on the Q3 FY26 results, Dr. Vikas Gupta, CEO of Alkem, said, “In Q3, we delivered a stable performance in a dynamic operating environment, supported by strong fundamentals in our domestic business and consistent execution across our international businesses. We remain bullish on the growth opportunities in domestic as well as international business and are on track to deliver our full year guidance. Looking ahead, the planned launch of our GLP-1 semaglutide in March 2026 is expected to be among our key growth drivers. Our focus remains on execution, strengthening our product portfolio, and building long-term competitiveness across markets.”

Key highlights of Q3 FY26 financial performance

- Total Revenue from Operations was ₹37,368 million, with YoY growth of 10.7%.
 - India sales were ₹24,959 million, YoY growth of 5.5%.
 - International sales were ₹12,157 million, with YoY growth of 26.6%.
- Earnings before Interest, Tax, Depreciation, and Amortisation (EBITDA) were ₹8,280 million, resulting in an EBITDA margin of 22.2% vs. 22.5% in Q3 FY25. EBITDA grew by 9.0% YoY.
- R&D expenses for Q3 FY26 were ₹1,390 million, or 3.7% of total revenue from operations, vs. ₹1,312 million in Q3 FY25 at 3.9% of total revenue from operations.

- Profit before tax (after exceptional item) was ₹7,812 million, YoY growth of 6.9%.
- Net Profit (after Non-Controlling interest) was ₹6,360 million, YoY growth of 1.6%.
- Exceptional item for the quarter includes the impact of ₹ 528 million on a preliminary basis related to the notification by the Government of India regarding the four Labour Codes.
- According to IQVIA (SSA) data, for Q3 FY26:
 - The Company registered a growth of 9.8% YoY vs Indian Pharmaceutical Market (IPM), which grew by 10.9%.
 - Acute segment reported growth of 8.6% vs IPM which grew by 7.8%, 80 bps outperformance.
 - Chronic segment reported growth of 15.8% vs. IPM which grew by 15.6%, 18 bps outperformance.

Operational Highlights

Domestic Business – Q3 FY26 Key Highlights

- India sales were ₹24,959 million, YoY growth of 5.5%.
- The contribution of domestic sales to total sales in Q3 FY26 was 67.2% vs. 71.1% in Q3 FY25.
- As per IQVIA (SSA) data, during the quarter, we have outperformed IPM in six therapies: Anti-infectives grew by ~1.4X, VMN ~2.0X, Pain ~1.4X, Anti-Diabetic ~1.2X, Respiratory ~1.2X, and Derma ~1.8X.

International Business – Q3 FY26 Key Highlights

- International sales were ₹12,157 million, YoY growth of 26.6%.
- US sales were ₹7,533 million, YoY growth of 18.8%.
- US business sales contributed 20.3% to total sales in Q3 FY26.
- Non-US sales were ₹4,624 million, YoY growth of 41.6%.
- Non-US business sales contributed 12.5% to total sales in Q3 FY26.
- During Q3 FY26, for the US market, the Company filed 02 ANDA and received 07 ANDAs approvals.
- As of December 31, 2025, the Company had filed 188 ANDAs, 02 NDAs and 01 BLA with the USFDA. It has received approvals for 167 ANDAs (including 20 tentative approvals) and 02 NDAs.

Facility Regulatory Status

Facility	Capability	Inspection Date	Regulatory Status
Baddi (India)	Formulations	Mar-24	EIR Received in June 2024
Daman (India)	Formulations	Aug-19	EIR Received in Oct 2019
Taloja R&D (India)	Bioequivalence Centre	Apr-25	No observation
Ankleshwar (India)	API	Apr-23	EIR Received in July 2023
Mandva (India)	API	Dec-23	EIR Received in Mar 2024
California (USA)	API	Sep-25	No observation
Note: USFDA conducted a virtual inspection at our manufacturing facilities in Daman from October 5th to 7th, 2020.			

About Alkem: Alkem Laboratories Ltd. is the fifth-largest pharmaceutical company in the Indian market, with a legacy spanning over 50 years of providing high-quality medicines to patients. It holds a dominant position in the therapy areas of anti-infectives, gastrointestinal disorders, pain management, and supplements. It also has a growing portfolio of products in chronic therapies, including diabetes, neurology, dermatology, and urology. It has 18 state-of-the-art manufacturing facilities and cutting-edge research and development (R&D) centres to develop and manufacture generic formulations, active pharmaceutical ingredients (APIs) and biosimilars. Apart from India, the company has a meaningful presence in the US, Latin America, Australia, and several other Asian countries. “Inspiring Healthier Lives” is at the core of the organization’s values and culture, reinforcing its steadfast commitment to improving global health. For more information, please visit www.alkemlabs.com and follow us on [LinkedIn](#), [Instagram](#), and [Facebook](#).

Contact

Investors:	Media:
Purvi Shah – Head of Investor Relations +91 84337 00890 purvi.shah@alkem.com +91-22-3982 9999 Ext: 9447	Isha Trivedi +91 98925 90003 alkemcorpcomm@alkem.com +91-22-3982 9999 Ext: 9672



Alkem Laboratories Ltd.

Q3 FY26 Results Presentation

13th February 2026



This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact, including, but not limited to, those that are identified by the use of words such as “anticipates”, “believes”, “estimates”, “expects”, “intends”, “plans”, “predicts”, “projects” and similar expressions. Risks and uncertainties that could affect us include, without limitation:

- General economic and business conditions in India and other key global markets in which we operate;
- The ability to successfully implement our strategy, our research and development efforts, growth & expansion plans and technological changes;
- Changes in the value of the Rupee and other currency changes;
- Changes in the Indian and international interest rates;
- Allocations of funds by the Governments in our key global markets;
- Changes in laws and regulations that apply to our customers, suppliers, and the pharmaceutical industry;
- Increasing competition in and the conditions of our customers, suppliers and the pharmaceutical industry; and
- Changes in political conditions in India and in our key global markets.

Should one or more of such risks and uncertainties materialize, or should any underlying assumption prove incorrect, actual outcomes may vary materially from those indicated in the applicable forward-looking statements. Any forward-looking statement or information contained in this presentation speaks only as of the date of the statement. We are not required to update any such statement or information to either reflect events or circumstances that occur after the date the statement or information is made or to account for unanticipated events, unless it is required by Law.

CONTENTS



Company's Financial Performance



Business Updates – Q3 FY26



Company overview and journey so far

Q3 FY26 Performance at Glance

Total Revenue from Operations

₹37,368 Mn

 **+10.7% YoY Growth**


EBITDA / Margin

₹8,280 Mn / 22.2%

 **+9.0% YoY Growth**

PAT¹ / Margin

₹6,360Mn / 17.0%

 **+1.6% YoY Growth**

Geographic-wise Break-Up

Domestic Business

₹24,959 Mn
+5.5% YoY Growth

International Business

₹12,157 Mn
+26.6% YoY Growth

Salient Numbers

₹55.9 Bn

Net Cash as of 31st Dec 2025

₹1,390 Mn

R&D spend for Q3 FY26

80 bps

Outperformance in the acute
segment vs. IPM

3.7%

R&D spend as % of sales during the
quarter

1. PAT: Profit after Non-Controlling Interest

Q3 FY26 – P&L Highlights

Particulars <i>(All figures in ₹ Mn)</i>	Q3FY26	Q3FY25	YoY growth	Q2FY26	QoQ growth	9MFY26	9MFY25	YoY growth
Revenue from Operations	37,368	33,743	10.7%	40,010	-6.6%	111,090	98,208	13.1%
Gross Profit	24,641	21,700	13.6%	26,000	-5.2%	72,641	63,358	14.7%
Gross Profit Margin	65.9%	64.3%		65.0%		65.4%	64.5%	
EBITDA	8,280	7,594	9.0%	9,208	-10.1%	24,878	21,209	17.3%
EBITDA Margin	22.2%	22.5%		23.0%		22.4%	21.6%	
PBT (before exceptional items)	8,340	7,311	14.1%	8,958	-6.9%	24,879	21,307	16.8%
Exceptional items¹	(528)	0		0		(399)	0	
PBT (after exceptional items)	7,812	7,311	6.9%	8,958	-12.8%	24,480	21,307	14.9%
PAT (after Non-Controlling interest)	6,360	6,258	1.6%	7,651	-16.9%	20,653	18,596	11.1%
PAT Margin	17.0%	18.5%		19.1%		18.6%	18.9%	
EPS (₹/share)	53.2	52.3	1.6%	64.0	-16.9%	172.8	155.5	11.1%

Notes: 1. Exceptional items for Q3 FY26 and 9M ended 31 Dec 2025 pertains to newly notified Labour Codes resulting in incremental impact; Exceptional items for 9M ended 31 Dec 2025, includes gain of ₹142.9 Mn from sale of the Indore facility.

CONTENTS



Company's Financial Performance




Business Updates – Q3 FY26



Company overview and journey so far

Domestic Business Performance

**Q3 FY26 sales of ₹24,959 Mn
(5.5% YoY growth)**





- Domestic business¹ revenue grew by 5.5% YoY to ₹24,959 Mn from ₹23,649 Mn during the same period last year.
- Domestic revenue contributed 67.2% to total sales in Q3 FY26.
- According to IQVIA (SSA) data, for Q3 FY26:
 - The Company registered a growth of 9.8% YoY, vs. the Indian Pharmaceutical Market (IPM), which also grew by 10.9%.
 - We've grown faster than the market in six of IPM's key therapy areas.
 - We have outperformed in the acute segment by 80 bps, growing at 8.6% vs IPM growth of 7.8%.
 - We have marginally outperformed in chronic category, i.e. 18 bps registering a growth of 15.8% vs IPM growth of 15.6%.









1. Includes revenue from Adroit and Bombay Ortho businesses.

Q3 FY26 - outpacing the market growth in six of the key focus therapies

Alkem growth vs. IPM growth




Outperformance in 6 of the key IPM focus therapies

Therapy Class	Growth YoY %	Market share %	IPM Rank – Value
 Anti Infectives	2.8% 3.8%	13.5% ↑ +0.1%	1 ↔
 Gastro Intestinal	8.1% 7.4%	8.0% ↓ - 0.1%	3 ↔
 VMN	11.1% 21.8%	6.9% ↑ +0.6%	2 ↔
 Pain / Analgesics	8.0% 11.2%	5.5% ↑ +0.2%	3 ↔
 Anti Diabetic	14.8% ★ 17.2%	2.3% ↔	13 ↑ +2
 Neuro / CNS	11.8% 11.0%	2.4% ↔	8 ↔
 Respiratory	11.8% 14.4%	1.6% ↔	15 ↑ +1
 Derma	8.8% 15.9%	1.6% ↑ +0.1%	18 ↑ +1

15+ years of unmatched leadership in the Anti-Infectives therapy


Q3 FY26 US Business sales of ₹7,533 Mn (18.8% YoY growth)



- US business revenue grew by 18.8% YoY to ₹7,533 Mn from ₹6,340 Mn during the same period last year.
- The strong growth was mainly on account of continued growth traction in new launches and volume increase.
- US revenue contributed 20.3% to total sales in Q3 FY26.
- During the Q3 FY26, the Company filed 02 ANDA, received 07 ANDA's approval.

US Market Filing and approvals status


ANDA / BLA Filings



As of December 31, 2025, the Company has **filed 188 ANDAs, 2 NDAs and 1 BLA** and has **received 167 ANDAs approvals** (including 20 tentative approvals) **and 2 NDAs approvals**.

Non-US Business Performance

**Q3 FY26 sales of ₹4,624Mn
(41.6% YoY growth)**




- Non-US business revenue grew by 41.6% YoY to ₹4,624 Mn from ₹3,265 Mn during the same period last year.
- Non-US revenue contributed 12.5% to total sales in Q3 FY26.
- The Non-US business growth was driven by strong growth across all markets.

Facility Regulatory Status

Facility	Capability	Inspection Date	Regulatory Status
Baddi (India)	Formulations	Mar-24	EIR Received in June 2024
Daman (India)	Formulations	Aug-19	EIR Received in Oct 2019
Taloja R&D (India)	Bioequivalence Centre	Apr-25	No observation
Ankleshwar (India)	API	Apr-23	EIR Received in July 2023
Mandva (India)	API	Dec-23	EIR Received in Mar 2024
California (USA)	API	Sep-25	No observation

Note: USFDA conducted a virtual inspection at our manufacturing facilities in Daman from October 5th to 7th, 2020.

Shareholding Pattern as on Dec 31, 2025



■ Promoter & Promoter Group ■ Non-Institution
■ Institution

BSE Ticker	539523
NSE Symbol	ALKEM
Shares Outstanding (Mn)	120
MCap (Rs in Mn)*	658, 302
Free Float MCap (Rs in Mn)	309, 139
Industry	Pharmaceuticals

**Share Price - Rs 5, 507 from NSE as of 31st Dec 25.*

Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks

Non-Institution – Public, Other Bodies Corporates, Clearing Members, Non-Resident Indians, Hindu Undivided Family and Trusts

CONTENTS



Company's Financial Performance



Business Updates – Q3 FY26



Company overview and journey so far

Alkem Laboratories at Glance (FY25)



Market Leadership

#3

Rank in
Prescriptions¹

#5

Rank by value in
IPM²

Leading Player

In the Trade
Generics segment

Top 3

Player in 4 out of top
7 largest IPM's TAs²



Scale

₹1,29,645 Mn

Total Revenue³

70.2%


Domestic Revenue

18

Brand families worth
₹1000 Mn+²

12,500+

Field force⁴



Profitability

63.3%

Gross Profit
Margin

19.4%

EBITDA Margin

16.7%

PAT Margin

28.1%

ROCE (Pre-Tax)

1. Prescriptions data as per SMSRC MAT Mar'25; 2. Market data as per IQVIA SSA MAT Mar'25; 3. Including Other Operating Income; 4. Excluding Line Managers as of 31st March 2025

Strong momentum from our mega brands has been pivotal in building robust brand franchises and consistently scaling them over the years

#2 'PAN'

Biggest Brand family in the IPM

17 Brands

in the IPM Top 300 ranks

35 Brands

Among the Top 3 ranks in their CVM¹ (Brands > ₹250 Mn)

Building large brand families defines our identity...

Brand Families	MAT Mar'20	MAT Mar'25	CAGR (5 Yrs.)
> ₹10 Bn	0	1	16.1%
> ₹5 Bn	1	1	7.7%
> ₹1.5 Bn	6	11	10.4%
> ₹500 Mn	11	12	13.2%

Brand family > ₹5 Bn

PAN **CLAVAM**

Brand family > ₹1.5 Bn









TAXIM **SUMOL** **CHERi**

50+ years of Alkem journey – a snapshot



1973

Inception of Alkem Laboratories Limited

1978

Established the first plant at Taloja, Mumbai



2003

First R&D facility established at Taloja



2006

Taxim became India's first anti-infective drug to surpass annual sales figure of ₹ 1 billion in the domestic market



2007

Filed the first ANDA in the US for the drug Amlodipine

2015

Successfully completed Initial Public Offering (IPO)

2014

Clavam surpassed ₹ 2 billion domestic sales milestone



2012

Acquired an API manufacturing facility in the US



2011

Acquired Enzene Biosciences, a Company engaged in the development of biosimilars in India



2010

Acquired Ascend Laboratories, a pharmaceutical Company in the US



2009

Received the first ANDA approval in the US for the drug Amlodipine. Acquired Pharmacor Pty. Ltd., a generic pharmaceutical Company in Australia



2018

Revenue from the US market crossed US\$ 200 million in annual sales

2019

Crossed the revenue milestone of US\$ 1 billion

2020

Started a new biologic/ biosimilar manufacturing facility in Pune

TGx business delivered 10+ billion topline

2021

First product launched from Enzene Biosciences in India

Company forayed in the respiratory segment in India with the launch of Pulmocare division

2022

Awarded as "Pharma Company of the Year" in ET India Pharma World Awards 2023

PAN franchise crossed ₹ 10 billion sales milestone

Clavam crossed ₹ 6 billion sales milestone



2023

50 years of Alkem



2024 - 25

Inclusion in the MSCI India Index

Adroit acquisition

Entry into the Medtech segment via licensing agreement with Exactech and acquisition of Bombay Ortho

Alkem & key subsidiaries



THANK YOU

For any queries, contact:
Purvi Shah – Head of Investor Relations

Mobile: +91 84337 00890

E-mail: purvi.shah@alkem.com

Tel: +91 22 3982 9999 Ext: 9447

Stay updated on     

Disclaimer: This is a confidential email from Alkem Laboratories Limited. The contents of this email and any attachments are solely intended for the addressee(s) and in all likelihood contain information that is legally privileged. If you are not the intended recipient of this email, you are on notice of its status and we request you to kindly advise us by return email immediately. Please also simultaneously disregard the contents herein, delete this email from your computer and server and also destroy any physical copies, if created. You are hereby notified that any use, any form of reproduction, dissemination, copying, disclosure, modification, distribution and/or publication of this e-mail, its contents or its attachment/s other than by its intended recipient/s is strictly prohibited and may be construed unlawful. Alkem Laboratories Limited does not accept any liability for the views expressed in this email or for the consequences of any viruses that may be transmitted with this email. The content of this email is subject to copyright and no part hereof may be reproduced, adapted or transmitted without the written consent of Alkem Laboratories Limited.